Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human Phase 1a/b, Open-Label, Multicenter, Dose Escalation, Optimization and Expansion Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

First-in-human Phase 1a/b, Open-Label, Multicenter, Dose Escalation, Optimization and Expansion Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ISM 5939 (Primary) ; Cisplatin; Docetaxel; Pembrolizumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors InSilico Medicine

    • Most Recent Events

    • 16 Dec 2024 New trial record
    • 21 Nov 2024 According to an Insilico Medicine media release, company announced that it has received IND clearance from FDA for ISM5939, for the treatment of solid tumors. The achievement marks the 10th AI-driven molecule self-developed by Insilico to be recognized with clearance to enter clinical trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top